Neutropenia

Most patients with acute myeloid leukemia who responded to treatment with venetoclax plus azacitidine in the VIALE-A study required dosing modifications to manage cytopenia, according to a presentation from ASH Annual Meeting and Exposition.

At our center, metrics obtained through our participation in CMS’s Oncology Care Model have allowed us to improve patient experience scores, reduce ED utilization and hospital admission, and impact several other measures of quality care.

The novel cereblon-modulating agent avadomide demonstrated preliminary clinical efficacy among patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1 study published in Blood.

Since having the good fortune to take on an editorial role for HemOnc Today, I have resisted the temptation to use the January editorial to provide a summary of highlights from ASH Annual Meeting and Exposition, or to enter the “reflective zone” at the turn of the year. Both seem a little predictable and formulaic.

Levofloxacin prophylaxis during the first few months of active myeloma treatment significantly reduced febrile episodes and mortality compared with placebo among a cohort of U.K. patients with newly diagnosed myeloma, according to results of the randomized phase 3 TEAMM study published in The Lancet Oncology.